| ²é¿´: 3489 | »Ø¸´: 13 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
[½»Á÷]
ÇóÖúÈçºÎ²éµ½ÍùÄêÖбêµÄ»ù½ðÉêÇëÊéÕªÒª
|
|||
| ±¾È˵ÚÒ»´ÎдÇàÄê»ù½ð£¬Éí±ßûÓÐÈË׫д£¬Ïë²Î¿¼Ò»Ï±ðÈ˵İ汾£¬ÔÚ¹ú»ùÍøÉÏÖ»Äܲ鵽ÏîÄ¿Ãû³ÆºÍ±àºÅ£¬ÄÄλ¸ßÈ˴ͽ̣ºµ½ÄÄ¿ÉÒԲ鵽ÒÑÖÐÏîÄ¿µÄÕªÒª£¿Ð»Ð» |
» ²ÂÄãϲ»¶
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÌåÖÆÄÚ³¤±²ËµÌåÖÆÄÚ¾ø´ó²¿·ÖÒ»±²×ÓÔڵײ㣬ÈçͬÄãÃÇÒ»Ñù´ó²¿·ÖÆÕͨ½ÌʦæÇÒÊÕÈëµÍ
ÒѾÓÐ13È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ11È˻ظ´
ΪʲôÖйú´óѧ¹¤¿Æ½ÌÊÚÃÇË®ÁËÄÇô¶àËùνµÄ¶¥»á¶¥¿¯£¬µ«»¹ÊÇ×ö²»³öÓîÊ÷»úÆ÷ÈË£¿
ÒѾÓÐ8È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ5È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ6È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ9È˻ظ´
ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼±
ÒѾÓÐ4È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÈçºÎÄܲ鵽¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÉêÇëÊéµÄÕªÒª£¿
ÒѾÓÐ5È˻ظ´
Ôõô¸øÉêÇëÊéÆðÃû×Ö£¬ÇóÖú°¡
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿Çó½ðÊô¸¯Ê´Óë·À»¤·½ÃæµÄÍùÄê¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÉêÇëÊé
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿¼±ÇóÖбêÐÂÊÀ¼ÍÓÅÐãÈ˲ÅÖ§³Ö¼Æ»®ÉêÇëÊé
ÒѾÓÐ11È˻ظ´
²ËÄñÇóÖú£¬¼ª°²ºóºÓµ÷²éÉêÇëÊéÖÐÁ¢ÏîÒÀ¾ÝºÍ¿ÉÐÐÐÔ·ÖÎöÈçºÎд£¿
ÒѾÓÐ19È˻ظ´
ÈçºÎ²éѯÍùÄêÖбêµÄ×ÔÈ»»ù½ðµÄÌâÄ¿ºÍÕªÒªµÈÐÅÏ¢£¿
ÒѾÓÐ3È˻ظ´
ÇóÖú£ºÇëÎʹú¼Ò×ÔÈ»¿ÆÑ§»ù½ðµÄ½á¹û´ÓÄÄÀï¿ÉÒԲ鵽£¿·Ç³£¸Ðл£¡
ÒѾÓÐ6È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
µ¥ÇúÑ»·¾ÃÁ˺ܶ඼»á±ä
+1/415
ÕÐÊÕÇÅÁº¹¤³Ì·½Ïò²©Ê¿Ñо¿Éú£¡
+3/137
ÄÏͨ´óѧÉúÎïÒ½Ò©·½Ïò¹ú¼Ò¼¶È˲ÅÍŶÓÕÐÆ¸½Ìʦ
+3/128
ÉϺ£½»Í¨´óѧҶÌìÄÏ¿ÎÌâ×éÕÐÆ¸2026¼¶²©Ê¿Ñо¿Éú
+1/96
¹ã¹¤-¶»ª·æ½ÌÊÚÍŶÓÕÐÊÕ²©Ê¿Éú£¨1ѧ²©-0-1ר²©£©
+1/81
ÕÐÆ¸ÆôÊ£¨Ã¸¹¤³ÌÓë·¢½Í¹¤³Ì·½Ïò£©
+2/72
°ÄÃÅÀí¹¤´óѧÈ˹¤ÖÇÄÜÖǻۿµÑø2026 Äê9ÔÂÈëѧ ²©Ê¿ÕÐÉúÓн±Ñ§½ð
+1/44
´óÁ¬º£Ê´óѧÂÖ»úѧԺÉÐÓв©Ê¿Ãû¶î
+2/40
Ó¢¹ú²¼Àï˹Íдóѧ³ÏÕв©Ê¿Éú£¬²©Ê¿ºóºÍÁªºÏÅàÑøÉú
+1/17
ÐÂÎ÷À¼ °Â¿ËÀ¼Àí¹¤´óѧ£¨AUT£©Õв©Ê¿£¬º£Ôå×ÊÔ´»¯·½Ïò£¬ÏêÇéÇë¼ûÈçÏÂÄÚÈÝ£¬Ð»Ð»£¡
+1/14
ÐÂ¼ÓÆÂÄÏÑóÀí¹¤´óѧ- ¹âµç/ ÖÇÄÜ´«¸Ð/ ÄÔ»ú½Ó¿Ú·½Ïò ²©Ê¿ºó
+1/13
²©Ê¿ÕÐÉú¡¢²©ºóÕÐÆ¸£¨ÖÐɽ´óѧԺʿÍŶÓ΢ÄɹâµçÆ÷¼þ¡¢ÈáÐÔµç×Ó·½Ïò£©
+2/8
²©Ê¿ÕÐÉú
+1/7
Öйú¿ÆÑ§¼¼Êõ´óѧ ¹¤³Ì¿ÆÑ§Ñ§Ôº ¹ú¼Ò¼¶È˲ÅÍÅ¶Ó ³ÏƸ²©Ê¿ºó
+1/5
Äϲý´óѧ×ÊÔ´Óë»·¾³Ñ§ÔºÁõ½ø½ÌÊÚÍŶÓÕÐÊÕ2026˶²©Ñо¿Éú
+1/5
¹ú×ÔÈ»B0706Ò©ÎﻯѧÉúÎïѧ£¬ÐèҪʲôÑùµÄÎÄÕ²ÅÄÜÖÐ
+1/4
Î人·ÄÖ¯´óѧȫ¹úÖØµãʵÑéÊÒ³ÂáɽÌÊÚÍŶÓÕÐÊÕ˶ʿÑо¿Éú
+1/3
°Ä¿Æ´óÕÐÊÕ2026ÇïÄÉÃ×ҽѧ/ÉúÎï²ÄÁÏ·½ÏòÈ«½±²©Ê¿Ñо¿Éú£¨3ÔÂ5ÈÕ18:00½ØÖ¹£©
+1/2
Î人Àí¹¤´óѧÊýѧÓëͳ¼ÆÑ§ÔºÕÅÐã¾ü½ÌÊÚ¿ÎÌâ×éÕÐÊÕ2026¼¶Çï¼¾²©Ê¿Ñо¿Éú
+1/1
Î人Àí¹¤´óѧÊýѧÓëͳ¼ÆÑ§ÔºÕÅÐã¾ü½ÌÊÚ¿ÎÌâ×éÕÐÊÕ2026¼¶Çï¼¾²©Ê¿Ñо¿Éú
+1/1
|
¸ÕÊÔÓùý£¬ÀýÈ磺 Ãû³Æ£º¹²±í´ïRSVÖкͿ¹ÔµÄDNAºÍ·Ç¸´ÖÆÐÍÏÙ²¡¶¾ÖØ×éÌåµÄ¹¹½¨¼°Æä±£»¤×÷Óà ------------------------------------------------------- ÖÐÎÄÕªÒª£º RSVÊǵ¼ÖÂÓ¤Ó×¶ùÑÏÖØÏºôÎüµÀ¸ÐȾµÄ×îÖØÒªµÄ²¡¶¾²¡Ô£¬Í¬Ê±Ò²ÊÇÒýÆðÀÏÈË·¢²¡ºÍËÀÍöµÄÖØÒªÔÒò¡£²¡¶¾¸ÐȾ»úÌåºóµÄÃâÒß±£»¤»úÖÆÉÐδÃ÷È·£¬Ò²ÎÞÌØÒìÐÔ·ÀÖη½·¨¡£ÒÔÕæºË±í´ïÖÊÁ£ºÍ·Ç¸´ÖÆÐÍÏÙ²¡¶¾ÎªÔØÌå¹²±í´ïRSVÁ½ÖÖÖкͿ¹ÔFºÍG£¬²¢Ñо¿ÆäÃâÒß±£»¤×÷ÓÃÊÇ̽Ë÷RSVÒßÃçµÄÓÐÒæ³¢ÊÔ¡£Ä¿Ç°£¬ÒѾÍê³ÉÑо¿¼Æ»®ÖеÄÒ»Ð©ÖØÒªÄÚÈÝ£¬ÈçÁ½ÖÖRSVÖкͿ¹Ô±àÂë»ùÒòµÄ¿Ë¡£¬ÖØ×éÏÙ²¡¶¾¼ò±ã¸ßЧµÄ¸Ä½¨·½·¨£¬¿É½øÐй²±í´ïµÄÏÙ²¡¶¾ÔØÌåϵͳµÄ¹¹½¨£¬·Ö±ð±í´ïFºÍGµ°°×µÄ·Ç¸´ÖÆÐÍÏÙ²¡¶¾ÖØ×éÌåµÄ¹¹½¨ºÍ¼ø¶¨¹¤×÷µÈ¡£ÒÑÅàÑøË¶Ê¿Ñо¿Éú3Ãû£¬·¢±íÂÛÎÄ4ƪ£¬ÆäÖкËÐÄÆÚ¿¯3ƪ¡£ÕâЩ¹¤×÷Ϊ¼ÌÐøÍê³ÉÓàϵĿÎÌâÈÎÎñµì¶¨ÁË»ù´¡¡£ ÖÐÎÄÖ÷Ìâ´Ê£º ºôÎüµÀºÏ°û²¡¶¾£»ÏÙ²¡¶¾ÖØ×éÌ壻ÃâÒß±£»¤×÷Óã»ÖкͿ¹Ô£»¹²±í´ï Ó¢ÎÄÕªÒª: Human respiratory syncytial virus (RSV) is the most important viral etiologic agent of pediatric lower respiratory tract disease worldwide. RSV disease is also responsible for considerable morbidity and mortality in the elderly. The mechanisms that contribute to the disease protection are not fully understood. Currently no safe and efficacious RSV vaccine is available. It will be helpful for the RSV vaccine program to investigate their expression and protective immunity of DNA and replication-defective adenoviral recombinants encoding the attachment (G) and fusion (F) protein. Till now, we have finished the clone and eukaryotic expression of F and G gene of subgroup A Long strain RSV, established a more effective and easier method for constructing recombinant adenovirus based on AdEasy System, constructed replication deficient adenovirus vector system used as expressing F and G protein simultaneously and the adenoviral recombinants expressing the F and G protein, respectively. All these achievements provide a good basis for further study. Ó¢ÎÄÖ÷Ìâ´Ê£º respiratory syncytial virus;protective immunity;adenovirus recombinant;neutralization antigen;co-expression |
9Â¥2011-02-20 20:47:51
¡ï
yunew80(½ð±Ò+1):лл²ÎÓë
yunew80(½ð±Ò+1): ºÜºÃ 2011-02-22 09:26:20
yunew80(½ð±Ò+1):лл²ÎÓë
yunew80(½ð±Ò+1): ºÜºÃ 2011-02-22 09:26:20
|
07ÄêÒÔǰµÄ¿ÉÒÔ´Ó»ù½ðί¾ÉÍøÕ¾²éÕªÒª¡£ |
3Â¥2011-02-20 13:38:08
4Â¥2011-02-20 14:28:10
|
http://npd.nsfc.gov.cn/ResearchNet_NSFC/index.aspx µã»÷-->ÉúÃü¿ÆÑ§²¿£¬ µã»÷-->×ÊÖúÏîÄ¿£¬ µã»÷-->±êÌ⣬ ×îºóµã»÷-->ÏîĿժҪ¡£ |
5Â¥2011-02-20 20:30:27













»Ø¸´´ËÂ¥